Dentsply Sirona Inc Stock Price, News & Analysis

Dentsply Sirona (Nasdaq: XRAY) has appointed Glenn Coleman as Executive Vice President and Chief Financial Officer, effective September 26, 2022. He succeeds Barbara Bodem, who served as Interim CFO since May 2022 and will assist Coleman until October 24, 2022. Coleman brings over 30 years of experience, having previously held executive roles at Integra Lifesciences and other global firms. CEO Simon Campion expressed confidence in Coleman’s leadership to enhance financial and operational strategies and support the company's growth initiatives.

Dentsply Sirona (Nasdaq: XRAY) unveiled new digital dentistry solutions at DS World 2022 in Las Vegas, aimed at enhancing efficiency and patient outcomes. A key feature is the Primescan Connect, a laptop-based intraoral scanner, designed for ease of use and integration. The product leverages the DS Core platform, enhancing connectivity and enabling streamlined workflows for treatment and diagnostics. Available from September 2022, these innovations promise to support dental practices in their operations while improving patient care.

Dentsply Sirona (Nasdaq: XRAY) announced the appointment of Simon Campion as President and CEO, effective September 12, 2022, succeeding John Groetelaars, who served as Interim CEO since April 2022. Campion joins from Becton, Dickinson and Company, bringing extensive experience in the medical device industry. His appointment is part of a strategic initiative to review and enhance the company's operations, competitive positioning, and capital structure. The Board highlighted Campion's record of operational expertise, sustainable growth, and potential to drive accountability and innovation.

Dentsply Sirona (Nasdaq: XRAY) announced on August 15, 2022, it remains non-compliant with Nasdaq Listing Rules, failing to file its Quarterly Reports on Form 10-Q for the first two quarters of 2022. Despite an earlier extension to file by August 14, the Company could not meet this deadline. An internal investigation regarding financial reporting matters is ongoing, complicating the filing process. Nasdaq may grant additional time to regain compliance, potentially extending the deadline to November 7, 2022. The notices received do not impact the current listing status of XRAY shares.

Dentsply Sirona (Nasdaq: XRAY) announced preliminary results for Q2 2022, expecting net sales over $1,005 million and adjusted EPS at or above $0.60. Despite year-over-year sales decline due to foreign exchange impacts, organic sales grew, driven by strong demand in Europe and recent product launches. An ongoing internal investigation into financial matters may delay the filing of its quarterly report. The company has declared a quarterly dividend of $0.125 per share, payable on October 14, 2022. Nasdaq compliance issues are also addressed, with an extension granted for filing the required reports.

DENTSPLY SIRONA Inc. (Nasdaq: XRAY) announced a quarterly cash dividend of $0.125 per share, indicating an annual rate of $0.50. This dividend is scheduled for payment on July 8, 2022, to shareholders of record as of June 24, 2022. Dentsply Sirona is recognized as the world’s largest manufacturer of professional dental products, providing innovative solutions that enhance patient care. The company has a strong portfolio of products and brands, reinforcing its commitment to the dental industry.

Dentsply Sirona (Nasdaq: XRAY) received a notification from Nasdaq on May 12, 2022, indicating non-compliance with listing rules due to the failure to file its Quarterly Report on Form 10-Q for the period ended March 31, 2022. The Company has 60 days to address this deficiency or submit a compliance plan. This notice does not immediately affect the stock's listing, and the Company aims to file the missing report as soon as possible. An investigation regarding the accounting of sales incentives is ongoing, which may have contributed to the delay.

Dentsply Sirona (Nasdaq: XRAY) reported Q1 2022 net sales of $965 million, a decrease of 6.1% from $1,027 million in Q1 2021. EPS dropped to $0.30, down 43.8%, while adjusted EPS decreased to $0.52 from $0.72. Operating income fell 39.5% to $93 million. Despite these declines, operating cash flow improved to $93 million. The company updated its FY2022 outlook, projecting organic sales growth of 2% to 3% and adjusted EPS between $2.35 and $2.55. Challenges stemmed from macroeconomic headwinds and weaker U.S. performance.